Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.

Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, Van Deerlin VM, Warren JD, Fox NC, Rossor MN, Mead S, Bocchetta M, Boeve BF, Knopman DS, Graff-Radford NR, Forsberg LK, Rademakers R, Wszolek ZK, van Swieten JC, Jiskoot LC, Meeter LH, Dopper EG, Papma JM, Snowden JS, Saxon J, Jones M, Pickering-Brown S, Le Ber I, Camuzat A, Brice A, Caroppo P, Ghidoni R, Pievani M, Benussi L, Binetti G, Dickerson BC, Lucente D, Krivensky S, Graff C, Öijerstedt L, Fallström M, Thonberg H, Ghoshal N, Morris JC, Borroni B, Benussi A, Padovani A, Galimberti D, Scarpini E, Fumagalli GG, Mackenzie IR, Hsiung GR, Sengdy P, Boxer AL, Rosen H, Taylor JB, Synofzik M, Wilke C, Sulzer P, Hodges JR, Halliday G, Kwok J, Sanchez-Valle R, Lladó A, Borrego-Ecija S, Santana I, Almeida MR, Tábuas-Pereira M, Moreno F, Barandiaran M, Indakoetxea B, Levin J, Danek A, Rowe JB, Cope TE, Otto M, Anderl-Straub S, de Mendonça A, Maruta C, Masellis M, Black SE, Couratier P, Lautrette G, Huey ED, Sorbi S, Nacmias B, Laforce R Jr, Tremblay ML, Vandenberghe R, Damme PV, Rogalski EJ, Weintraub S, Gerhard A, Onyike CU, Ducharme S, Papageorgiou SG, Lyn AS, Brodtmann A, Finger E, Guerreiro R, Bras J, Rohrer JD; FTD Prevention Initiative.

Lancet Neurol. 2019 Dec 3. pii: S1474-4422(19)30394-1. doi: 10.1016/S1474-4422(19)30394-1. [Epub ahead of print]

2.

Parkinsonism in frontotemporal dementias.

Rowe JB.

Int Rev Neurobiol. 2019;149:249-275. doi: 10.1016/bs.irn.2019.10.012. Epub 2019 Nov 21.

PMID:
31779815
3.

Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.

van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP, Papma JM, de Jong FJ, Verberk IMW, Teunissen C, Rizopoulos D, Heller C, Convery RS, Moore KM, Bocchetta M, Neason M, Cash DM, Borroni B, Galimberti D, Sanchez-Valle R, Laforce R Jr, Moreno F, Synofzik M, Graff C, Masellis M, Carmela Tartaglia M, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler C, Ducharme S, Gerhard A, Danek A, Levin J, Otto M, Frisoni GB, Cappa S, Pijnenburg YAL, Rohrer JD, van Swieten JC; Genetic Frontotemporal dementia Initiative (GENFI).

Lancet Neurol. 2019 Dec;18(12):1103-1111. doi: 10.1016/S1474-4422(19)30354-0.

PMID:
31701893
4.

Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features.

Low A, Mak E, Malpetti M, Chouliaras L, Nicastro N, Su L, Holland N, Rittman T, Rodríguez PV, Passamonti L, Bevan-Jones WR, Jones PS, Rowe JB, O'Brien JT.

Alzheimers Dement (Amst). 2019 Oct 1;11:690-699. doi: 10.1016/j.dadm.2019.08.001. eCollection 2019 Dec.

5.

18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy.

Nicastro N, Rodriguez PV, Malpetti M, Bevan-Jones WR, Simon Jones P, Passamonti L, Aigbirhio FI, O'Brien JT, Rowe JB.

J Neurol. 2019 Oct 22. doi: 10.1007/s00415-019-09566-9. [Epub ahead of print]

PMID:
31641878
6.

Cognitive Diversity in a Healthy Aging Cohort: Cross-Domain Cognition in the Cam-CAN Project.

Shafto MA, Henson RN, Matthews FE, Taylor JR, Emery T, Erzinclioglu S, Hanley C, Rowe JB, Cusack R, Calder AJ, Marslen-Wilson WD, Duncan J, Dalgleish T, Brayne C, Cam-Can, Tyler LK.

J Aging Health. 2019 Oct 8:898264319878095. doi: 10.1177/0898264319878095. [Epub ahead of print]

PMID:
31592706
7.

Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.

Respondek G, Grimm MJ, Piot I, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Roeber S, Giese A, Grossman M, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Höglinger GU; Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group.

Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27872. [Epub ahead of print]

PMID:
31571273
8.

Perceptual and conceptual processing of visual objects across the adult lifespan.

Bruffaerts R, Tyler LK, Shafto M, Tsvetanov KA; Cambridge Centre for Ageing and Neuroscience, Clarke A.

Sci Rep. 2019 Sep 24;9(1):13771. doi: 10.1038/s41598-019-50254-5.

9.

Evidence of a Causal Association Between Cancer and Alzheimer's Disease: a Mendelian Randomization Analysis.

Seddighi S, Houck AL, Rowe JB, Pharoah PDP.

Sci Rep. 2019 Sep 19;9(1):13548. doi: 10.1038/s41598-019-49795-6.

10.

11 C-PK11195 PET imaging and white matter changes in Parkinson's disease dementia.

Nicastro N, Surendranathan A, Mak E, Rowe JB, O'Brien JT.

Ann Clin Transl Neurol. 2019 Oct;6(10):2133-2136. doi: 10.1002/acn3.50877. Epub 2019 Sep 10.

11.
12.

Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography.

Hughes LE, Henson RN, Pereda E, Bruña R, López-Sanz D, Quinn AJ, Woolrich MW, Nobre AC, Rowe JB, Maestú F; BioFIND Working Group.

Alzheimers Dement (Amst). 2019 Jun 14;11:450-462. doi: 10.1016/j.dadm.2019.04.009. eCollection 2019 Dec.

13.

European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND).

Düzel E, Acosta-Cabronero J, Berron D, Biessels GJ, Björkman-Burtscher I, Bottlaender M, Bowtell R, Buchem MV, Cardenas-Blanco A, Boumezbeur F, Chan D, Clare S, Costagli M, de Rochefort L, Fillmer A, Gowland P, Hansson O, Hendrikse J, Kraff O, Ladd ME, Ronen I, Petersen E, Rowe JB, Siebner H, Stoecker T, Straub S, Tosetti M, Uludag K, Vignaud A, Zwanenburg J, Speck O.

Alzheimers Dement (Amst). 2019 Jul 31;11:538-549. doi: 10.1016/j.dadm.2019.04.010. eCollection 2019 Dec.

14.

Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia.

Bonham LW, Steele NZR, Karch CM, Broce I, Geier EG, Wen NL, Momeni P, Hardy J, Miller ZA, Gorno-Tempini ML, Hess CP, Lewis P, Miller BL, Seeley WW, Manzoni C, Desikan RS, Baranzini SE, Ferrari R, Yokoyama JS; International FTD-Genomics Consortium (IFGC).

Sci Rep. 2019 Jul 26;9(1):10854. doi: 10.1038/s41598-019-46415-1.

15.

Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases.

Betts MJ, Kirilina E, Otaduy MCG, Ivanov D, Acosta-Cabronero J, Callaghan MF, Lambert C, Cardenas-Blanco A, Pine K, Passamonti L, Loane C, Keuken MC, Trujillo P, Lüsebrink F, Mattern H, Liu KY, Priovoulos N, Fliessbach K, Dahl MJ, Maaß A, Madelung CF, Meder D, Ehrenberg AJ, Speck O, Weiskopf N, Dolan R, Inglis B, Tosun D, Morawski M, Zucca FA, Siebner HR, Mather M, Uludag K, Heinsen H, Poser BA, Howard R, Zecca L, Rowe JB, Grinberg LT, Jacobs HIL, Düzel E, Hämmerer D.

Brain. 2019 Sep 1;142(9):2558-2571. doi: 10.1093/brain/awz193.

16.

Language impairment in progressive supranuclear palsy and corticobasal syndrome.

Peterson KA, Patterson K, Rowe JB.

J Neurol. 2019 Jul 18. doi: 10.1007/s00415-019-09463-1. [Epub ahead of print] Review.

PMID:
31321513
17.

Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance.

Passamonti L, Tsvetanov KA, Jones PS, Bevan-Jones WR, Arnold R, Borchert RJ, Mak E, Su L, O'Brien JT, Rowe JB.

J Neurosci. 2019 Sep 4;39(36):7218-7226. doi: 10.1523/JNEUROSCI.2574-18.2019. Epub 2019 Jul 18.

18.

Connectomics and molecular imaging in neurodegeneration.

Bischof GN, Ewers M, Franzmeier N, Grothe MJ, Hoenig M, Kocagoncu E, Neitzel J, Rowe JB, Strafella A, Drzezga A, van Eimeren T; MINC faculty.

Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2819-2830. doi: 10.1007/s00259-019-04394-5. Epub 2019 Jul 11.

PMID:
31292699
19.

Test Your Memory (TYM test): diagnostic evaluation of patients with non-Alzheimer dementias.

Brown J, Wiggins J, Lansdall CJ, Dawson K, Rittman T, Rowe JB.

J Neurol. 2019 Oct;266(10):2546-2553. doi: 10.1007/s00415-019-09447-1. Epub 2019 Jul 2.

20.

In Vivo Assay of Cortical Microcircuitry in Frontotemporal Dementia: A Platform for Experimental Medicine Studies.

Shaw AD, Hughes LE, Moran R, Coyle-Gilchrist I, Rittman T, Rowe JB.

Cereb Cortex. 2019 Jun 19. pii: bhz024. doi: 10.1093/cercor/bhz024. [Epub ahead of print]

PMID:
31216360
21.

Meta-analytic Evidence for the Plurality of Mechanisms in Transdiagnostic Structural MRI Studies of Hallucination Status.

Rollins CPE, Garrison JR, Simons JS, Rowe JB, O'Callaghan C, Murray GK, Suckling J.

EClinicalMedicine. 2019 Feb 21;8:57-71. doi: 10.1016/j.eclinm.2019.01.012. eCollection 2019 Feb.

22.

Education modulates brain maintenance in presymptomatic frontotemporal dementia.

Gazzina S, Grassi M, Premi E, Cosseddu M, Alberici A, Archetti S, Gasparotti R, Van Swieten J, Galimberti D, Sanchez-Valle R, Laforce RJ, Moreno F, Synofzik M, Graff C, Masellis M, Tartaglia MC, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler CR, Ducharme S, Gerhard A, Danek A, Levin J, Otto M, Frisoni G, Sorbi S, Padovani A, Rohrer JD, Borroni B; Genetic FTD Initiative, GENFI.

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1124-1130. doi: 10.1136/jnnp-2019-320439. Epub 2019 Jun 10.

PMID:
31182509
23.

Inflammation and cerebral small vessel disease: A systematic review.

Low A, Mak E, Rowe JB, Markus HS, O'Brien JT.

Ageing Res Rev. 2019 Aug;53:100916. doi: 10.1016/j.arr.2019.100916. Epub 2019 Jun 10. Review.

PMID:
31181331
24.

The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration.

Passamonti L, Lansdall CJ, Rowe JB.

Curr Opin Behav Sci. 2018 Aug;22:14-20. doi: 10.1016/j.cobeha.2017.12.015.

25.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

26.

ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-β copathology.

Koriath C, Lashley T, Taylor W, Druyeh R, Dimitriadis A, Denning N, Williams J, Warren JD, Fox NC, Schott JM, Rowe JB, Collinge J, Rohrer JD, Mead S.

Alzheimers Dement (Amst). 2019 Mar 19;11:277-280. doi: 10.1016/j.dadm.2019.01.010. eCollection 2019 Dec.

27.

Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease.

Koychev I, Lawson J, Chessell T, Mackay C, Gunn R, Sahakian B, Rowe JB, Thomas AJ, Rochester L, Chan D, Tom B, Malhotra P, Ballard C, Chessell I, Ritchie CW, Raymont V, Leroi I, Lengyel I, Murray M, Thomas DL, Gallacher J, Lovestone S.

BMJ Open. 2019 Mar 23;9(3):e024498. doi: 10.1136/bmjopen-2018-024498.

28.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Aug;34(8):1228-1232. doi: 10.1002/mds.27666. Epub 2019 Mar 18.

29.

Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.

Jabbari E, Woodside J, Guo T, Magdalinou NK, Chelban V, Athauda D, Lees AJ, Foltynie T, Houlden H, Church A, Hu MT, Rowe JB, Zetterberg H, Morris HR.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):768-773. doi: 10.1136/jnnp-2018-320151. Epub 2019 Mar 13.

30.

Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study.

Mutsaerts HJMM, Mirza SS, Petr J, Thomas DL, Cash DM, Bocchetta M, de Vita E, Metcalfe AWS, Shirzadi Z, Robertson AD, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Keren R, Rogaeva E, van Swieten J, Laforce R, Tagliavini F, Borroni B, Galimberti D, Rowe JB, Graff C, Frisoni GB, Finger E, Sorbi S, de Mendonça A, Rohrer JD, MacIntosh BJ, Masellis M; GENetic Frontotemporal dementia Initiative (GENFI).

Brain. 2019 Apr 1;142(4):1108-1120. doi: 10.1093/brain/awz039. Erratum in: Brain. 2019 Jun 1;142(6):e28.

31.

In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier.

Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer T, Arnold R, Coles JP, Aigbirhio FI, O'Brien JT, Rowe JB.

Ann Clin Transl Neurol. 2019 Jan 2;6(2):373-378. doi: 10.1002/acn3.683. eCollection 2019 Feb.

32.

Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration.

Lansdall CJ, Coyle-Gilchrist ITS, Vázquez Rodríguez P, Wilcox A, Wehmann E, Robbins TW, Rowe JB.

Neurology. 2019 Apr 2;92(14):e1547-e1557. doi: 10.1212/WNL.0000000000007249. Epub 2019 Mar 6.

33.

Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia.

Rittman T, Borchert R, Jones S, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, Mendonça A, Sorbi S, Rohrer JD, Rowe JB; Genetic Frontotemporal Dementia Initiative (GENFI).

Neurobiol Aging. 2019 May;77:169-177. doi: 10.1016/j.neurobiolaging.2018.12.009. Epub 2019 Jan 4.

34.

Disease-informed brain mapping teaches important lessons about the human brain.

Dagher A, Lehéricy S, Rowe JB, Siebner HR.

Neuroimage. 2019 Apr 15;190:1-3. doi: 10.1016/j.neuroimage.2019.02.040. Epub 2019 Feb 21. No abstract available.

PMID:
30798013
35.

Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort.

Cury C, Durrleman S, Cash DM, Lorenzi M, Nicholas JM, Bocchetta M, van Swieten JC, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, de Mendonça A, Sorbi S, Ourselin S, Rohrer JD, Modat M; Genetic FTD Initiative, GENFI.

Neuroimage. 2019 Mar;188:282-290. doi: 10.1016/j.neuroimage.2018.11.063. Epub 2018 Dec 6.

36.

Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia.

Swarup V, Hinz FI, Rexach JE, Noguchi KI, Toyoshiba H, Oda A, Hirai K, Sarkar A, Seyfried NT, Cheng C, Haggarty SJ; International Frontotemporal Dementia Genomics Consortium, Grossman M, Van Deerlin VM, Trojanowski JQ, Lah JJ, Levey AI, Kondou S, Geschwind DH.

Nat Med. 2019 Jan;25(1):152-164. doi: 10.1038/s41591-018-0223-3. Epub 2018 Dec 3.

37.

Publisher Correction: Sensory attenuation in Parkinson's disease is related to disease severity and dopamine dose.

Wolpe N, Zhang J, Nombela C, Ingram JN, Wolpert DM; Cam-CAN, Rowe JB.

Sci Rep. 2018 Nov 22;8(1):17429. doi: 10.1038/s41598-018-35439-8.

38.

The role of dopamine in the brain - lessons learned from Parkinson's disease.

Meder D, Herz DM, Rowe JB, Lehéricy S, Siebner HR.

Neuroimage. 2019 Apr 15;190:79-93. doi: 10.1016/j.neuroimage.2018.11.021. Epub 2018 Nov 20. Review.

39.

Directly Measuring the Rate of Slacking as Stroke Survivors produced Isometric Forces during a Tracking Task.

Smith BW, Rowe JB, Reinkensmeyer DJ.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:2519-2522. doi: 10.1109/EMBC.2018.8512740.

PMID:
30440920
40.

In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease.

Mak E, Bethlehem RAI, Romero-Garcia R, Cervenka S, Rittman T, Gabel S, Surendranathan A, Bevan-Jones RW, Passamonti L, Vázquez Rodríguez P, Su L, Arnold R, Williams GB, Hong YT, Fryer TD, Aigbirhio FI, Rowe JB, O'Brien JT.

Alzheimers Dement (Amst). 2018 Sep 17;10:678-687. doi: 10.1016/j.dadm.2018.08.005. eCollection 2018.

41.

Strong and specific associations between cardiovascular risk factors and white matter micro- and macrostructure in healthy aging.

Fuhrmann D, Nesbitt D, Shafto M, Rowe JB, Price D, Gadie A; Cam-CAN, Kievit RA.

Neurobiol Aging. 2019 Feb;74:46-55. doi: 10.1016/j.neurobiolaging.2018.10.005. Epub 2018 Oct 12.

42.

Early microglial activation and peripheral inflammation in dementia with Lewy bodies.

Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R, Vázquez Rodríguez P, Bevan-Jones WR, Brain SAE, Fryer TD, Aigbirhio FI, Rowe JB, O'Brien JT.

Brain. 2018 Dec 1;141(12):3415-3427. doi: 10.1093/brain/awy265.

43.

Sensory attenuation in Parkinson's disease is related to disease severity and dopamine dose.

Wolpe N, Zhang J, Nombela C, Ingram JN, Wolpert DM; Cam-CAN, Rowe JB.

Sci Rep. 2018 Oct 23;8(1):15643. doi: 10.1038/s41598-018-33678-3. Erratum in: Sci Rep. 2018 Nov 22;8(1):17429.

44.

[18F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion.

Bevan-Jones RW, Cope TE, Jones SP, Passamonti L, Hong YT, Fryer T, Arnold R, Coles JP, Aigbirhio FA, Patterson K, O'Brien JT, Rowe JB.

Ann Clin Transl Neurol. 2018 Sep 14;5(10):1292-1296. doi: 10.1002/acn3.631. eCollection 2018 Oct.

45.

Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference.

Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, de Mendonça A, Sorbi S, Warren JD, Crutch S, Fox NC, Ourselin S, Schott JM, Rohrer JD, Alexander DC; Genetic FTD Initiative (GENFI); Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Nat Commun. 2018 Oct 15;9(1):4273. doi: 10.1038/s41467-018-05892-0.

46.

Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans.

Skandali N, Rowe JB, Voon V, Deakin JB, Cardinal RN, Cormack F, Passamonti L, Bevan-Jones WR, Regenthal R, Chamberlain SR, Robbins TW, Sahakian BJ.

Neuropsychopharmacology. 2018 Dec;43(13):2645-2651. doi: 10.1038/s41386-018-0229-z. Epub 2018 Sep 26.

47.

Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.

Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, Quinn L, Mok TH, Dimitriadis A, Norsworthy P, Bass N, Carter J, Walker Z, Kipps C, Coulthard E, Polke JM, Bernal-Quiros M, Denning N, Thomas R, Raybould R, Williams J, Mummery CJ, Wild EJ, Houlden H, Tabrizi SJ, Rossor MN, Hummerich H, Warren JD, Rowe JB, Rohrer JD, Schott JM, Fox NC, Collinge J, Mead S.

Mol Psychiatry. 2018 Oct 2. doi: 10.1038/s41380-018-0224-0. [Epub ahead of print]

48.

A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers.

Zhang M, Ferrari R, Tartaglia MC, Keith J, Surace EI, Wolf U, Sato C, Grinberg M, Liang Y, Xi Z, Dupont K, McGoldrick P, Weichert A, McKeever PM, Schneider R, McCorkindale MD, Manzoni C, Rademakers R, Graff-Radford NR, Dickson DW, Parisi JE, Boeve BF, Petersen RC, Miller BL, Seeley WW, van Swieten JC, van Rooij J, Pijnenburg Y, van der Zee J, Van Broeckhoven C, Le Ber I, Van Deerlin V, Suh E, Rohrer JD, Mead S, Graff C, Öijerstedt L, Pickering-Brown S, Rollinson S, Rossi G, Tagliavini F, Brooks WS, Dobson-Stone C, Halliday GM, Hodges JR, Piguet O, Binetti G, Benussi L, Ghidoni R, Nacmias B, Sorbi S, Bruni AC, Galimberti D, Scarpini E, Rainero I, Rubino E, Clarimon J, Lleó A, Ruiz A, Hernández I, Pastor P, Diez-Fairen M, Borroni B, Pasquier F, Deramecourt V, Lebouvier T, Perneczky R, Diehl-Schmid J, Grafman J, Huey ED, Mayeux R, Nalls MA, Hernandez D, Singleton A, Momeni P, Zeng Z, Hardy J, Robertson J, Zinman L, Rogaeva E; International FTD-Genomics Consortium (IFGC).

Brain. 2018 Oct 1;141(10):2895-2907. doi: 10.1093/brain/awy238.

49.

Reply: Brain oscillations, inhibition and social inappropriateness in frontotemporal degeneration.

Hughes LE, Rittman T, Robbins TW, Rowe JB.

Brain. 2018 Oct 1;141(10):e74. doi: 10.1093/brain/awy235. No abstract available.

PMID:
30212860
50.

Aβ42/Aβ40 and Aβ42/Aβ38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study.

Koychev I, Galna B, Zetterberg H, Lawson J, Zamboni G, Ridha BH, Rowe JB, Thomas A, Howard R, Malhotra P, Ritchie C, Lovestone S, Rochester L.

J Alzheimers Dis. 2018;65(4):1377-1383. doi: 10.3233/JAD-180622.

Supplemental Content

Loading ...
Support Center